Laser ablation of abnormal neurological tissue using robotic neuroblate system (laantern): 12-month outcomes and quality of life after brain tumor ablation

Albert H. Kim, Steven Tatter, Ganesh Rao, Sujit Prabhu, Clark Chen, Peter Fecci, Veronica Chiang, Kris Smith, Brian J. Williams, Alireza M. Mohammadi, Kevin Judy, Andrew Sloan, Zulma Tovar-Spinoza, James Baumgartner, Constantinos Hadjipanayis, Eric C. Leuthardt

Research output: Contribution to journalArticlepeer-review

39 Scopus citations


BACKGROUND: Laser Ablation of Abnormal Neurological Tissue using Robotic NeuroBlate System (LAANTERN) is an ongoing multicenter prospective NeuroBlate (Monteris Medical) LITT (laser interstitial thermal therapy) registry collecting real-world outcomes and quality-of-life (QoL) data. OBJECTIVE: To compare 12-mo outcomes from all subjects undergoing LITT for intracranial tumors/neoplasms. METHODS: Demographics, intraprocedural data, adverse events, QoL, hospitalizations, health economics, and survival data are collected; standard data management and monitoring occur. RESULTS: A total of 14 centers enrolled 223 subjects; the median follow-up was 223 d. There were 119 (53.4%) females and 104 (46.6%) males. The median age was 54.3 yr (range 3-86) and 72.6% had at least 1 baseline comorbidity. The median baseline Karnofsky Performance Score (KPS) was 90. Of the ablated tumors, 131 were primary and 92 were metastatic. Most patients with primary tumors had high-grade gliomas (80.9%). Patients with metastatic cancer had recurrence (50.6%) or radiation necrosis (40%). The median postprocedure hospital stay was 33.4 h (12.7-733.4). The 1-yr estimated survival rate was 73%, and this was not impacted by disease etiology. Patient-reported QoL as assessed by the Functional Assessment of Cancer Therapy-Brain was stabilized postprocedure. KPS declined by an average of 5.7 to 10.5 points postprocedure; however, 50.5% had stabilized/improved KPS at 6 mo. There were no significant differences in KPS or QoL between patients with metastatic vs primary tumors. CONCLUSION: Results from the ongoing LAANTERN registry demonstrate that LITT stabilizes and improves QoL from baseline levels in a malignant brain tumor patient population with high rates of comorbidities. Overall survival was better than anticipated for a real-world registry and comparative to published literature.

Original languageEnglish
Pages (from-to)E338-E346
Issue number3
StatePublished - Sep 1 2020


  • Brain tumor
  • LITT
  • Laser ablation
  • Quality of life
  • Survival


Dive into the research topics of 'Laser ablation of abnormal neurological tissue using robotic neuroblate system (laantern): 12-month outcomes and quality of life after brain tumor ablation'. Together they form a unique fingerprint.

Cite this